PortalPublikationenThe Validated Investigator Global Assessment for Atopic Derm...

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

Standard

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. / Simpson, Eric; Bissonnette, Robert; Eichenfield, Lawrence F; Guttman-Yassky, Emma; King, Brett; Silverberg, Jonathan I; Beck, Lisa A; Bieber, Thomas; Reich, Kristian; Kabashima, Kenji; Seyger, Marieke; Siegfried, Elaine; Stingl, Georg; Feldman, Steven R; Menter, Alan; van de Kerkhof, Peter; Yosipovitch, Gil; Paul, Carle; Martel, Philippe; Dubost-Brama, Ariane; Armstrong, John; Chavda, Rajeev; Frey, Steve; Joubert, Yolandi; Milutinovic, Marina; Parneix, Anne; Teixeira, Henrique D; Lin, Chen-Yen; Sun, Luna; Klekotka, Paul; Nickoloff, Brian; Dutronc, Yves; Mallbris, Lotus; Janes, Jonathan M; DeLozier, Amy M; Nunes, Fabio P; Paller, Amy S.

in: J AM ACAD DERMATOL, Jahrgang 83, Nr. 3, 09.2020, S. 839-846.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Simpson, E, Bissonnette, R, Eichenfield, LF, Guttman-Yassky, E, King, B, Silverberg, JI, Beck, LA, Bieber, T, Reich, K, Kabashima, K, Seyger, M, Siegfried, E, Stingl, G, Feldman, SR, Menter, A, van de Kerkhof, P, Yosipovitch, G, Paul, C, Martel, P, Dubost-Brama, A, Armstrong, J, Chavda, R, Frey, S, Joubert, Y, Milutinovic, M, Parneix, A, Teixeira, HD, Lin, C-Y, Sun, L, Klekotka, P, Nickoloff, B, Dutronc, Y, Mallbris, L, Janes, JM, DeLozier, AM, Nunes, FP & Paller, AS 2020, 'The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis', J AM ACAD DERMATOL, Jg. 83, Nr. 3, S. 839-846. https://doi.org/10.1016/j.jaad.2020.04.104

APA

Simpson, E., Bissonnette, R., Eichenfield, L. F., Guttman-Yassky, E., King, B., Silverberg, J. I., Beck, L. A., Bieber, T., Reich, K., Kabashima, K., Seyger, M., Siegfried, E., Stingl, G., Feldman, S. R., Menter, A., van de Kerkhof, P., Yosipovitch, G., Paul, C., Martel, P., ... Paller, A. S. (2020). The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J AM ACAD DERMATOL, 83(3), 839-846. https://doi.org/10.1016/j.jaad.2020.04.104

Vancouver

Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J AM ACAD DERMATOL. 2020 Sep;83(3):839-846. https://doi.org/10.1016/j.jaad.2020.04.104

Bibtex

@article{a0afebc0aacf47fa86d63e103fbd844d,
title = "The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis",
abstract = "BACKGROUND: An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization.OBJECTIVES: To develop an IGA scale, training module, and clinical certification examination for use in AD trials; establish content validity; and assess reliability.METHODS: Expert dermatologists participated in the development of the validated IGA for AD (vIGA-ADTM). Reliability (interrater and intrarater) was assessed by 2 web-based surveys. Clinical certification for investigators consisted of a training module and examination.RESULTS: Expert consensus was achieved around a 5-point IGA scale including morphologic descriptions, and content validity was established. Survey 1 showed strong interrater reliability (Kendall's coefficient of concordance W [Kendall's W], 0.809; intraclass correlation [ICC], 0.817) and excellent agreement (weighted kappa, 0.857). Survey 2, completed 5 months after training of dermatologists, showed improvements in scale reliability (Kendall's W, 0.819; ICC, 0.852; weighted kappa, 0.889). In this study, 627 investigators completed vIGA-AD training and certification.LIMITATIONS: Ratings were assessed on photographs.CONCLUSION: A validated IGA scale and training module were developed with the intent of harmonizing assessment of disease severity in AD trials. Strong reliability and excellent agreement between assessments were observed.",
author = "Eric Simpson and Robert Bissonnette and Eichenfield, {Lawrence F} and Emma Guttman-Yassky and Brett King and Silverberg, {Jonathan I} and Beck, {Lisa A} and Thomas Bieber and Kristian Reich and Kenji Kabashima and Marieke Seyger and Elaine Siegfried and Georg Stingl and Feldman, {Steven R} and Alan Menter and {van de Kerkhof}, Peter and Gil Yosipovitch and Carle Paul and Philippe Martel and Ariane Dubost-Brama and John Armstrong and Rajeev Chavda and Steve Frey and Yolandi Joubert and Marina Milutinovic and Anne Parneix and Teixeira, {Henrique D} and Chen-Yen Lin and Luna Sun and Paul Klekotka and Brian Nickoloff and Yves Dutronc and Lotus Mallbris and Janes, {Jonathan M} and DeLozier, {Amy M} and Nunes, {Fabio P} and Paller, {Amy S}",
note = "Copyright {\textcopyright} 2020. Published by Elsevier Inc.",
year = "2020",
month = sep,
doi = "10.1016/j.jaad.2020.04.104",
language = "English",
volume = "83",
pages = "839--846",
journal = "J AM ACAD DERMATOL",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

AU - Simpson, Eric

AU - Bissonnette, Robert

AU - Eichenfield, Lawrence F

AU - Guttman-Yassky, Emma

AU - King, Brett

AU - Silverberg, Jonathan I

AU - Beck, Lisa A

AU - Bieber, Thomas

AU - Reich, Kristian

AU - Kabashima, Kenji

AU - Seyger, Marieke

AU - Siegfried, Elaine

AU - Stingl, Georg

AU - Feldman, Steven R

AU - Menter, Alan

AU - van de Kerkhof, Peter

AU - Yosipovitch, Gil

AU - Paul, Carle

AU - Martel, Philippe

AU - Dubost-Brama, Ariane

AU - Armstrong, John

AU - Chavda, Rajeev

AU - Frey, Steve

AU - Joubert, Yolandi

AU - Milutinovic, Marina

AU - Parneix, Anne

AU - Teixeira, Henrique D

AU - Lin, Chen-Yen

AU - Sun, Luna

AU - Klekotka, Paul

AU - Nickoloff, Brian

AU - Dutronc, Yves

AU - Mallbris, Lotus

AU - Janes, Jonathan M

AU - DeLozier, Amy M

AU - Nunes, Fabio P

AU - Paller, Amy S

N1 - Copyright © 2020. Published by Elsevier Inc.

PY - 2020/9

Y1 - 2020/9

N2 - BACKGROUND: An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization.OBJECTIVES: To develop an IGA scale, training module, and clinical certification examination for use in AD trials; establish content validity; and assess reliability.METHODS: Expert dermatologists participated in the development of the validated IGA for AD (vIGA-ADTM). Reliability (interrater and intrarater) was assessed by 2 web-based surveys. Clinical certification for investigators consisted of a training module and examination.RESULTS: Expert consensus was achieved around a 5-point IGA scale including morphologic descriptions, and content validity was established. Survey 1 showed strong interrater reliability (Kendall's coefficient of concordance W [Kendall's W], 0.809; intraclass correlation [ICC], 0.817) and excellent agreement (weighted kappa, 0.857). Survey 2, completed 5 months after training of dermatologists, showed improvements in scale reliability (Kendall's W, 0.819; ICC, 0.852; weighted kappa, 0.889). In this study, 627 investigators completed vIGA-AD training and certification.LIMITATIONS: Ratings were assessed on photographs.CONCLUSION: A validated IGA scale and training module were developed with the intent of harmonizing assessment of disease severity in AD trials. Strong reliability and excellent agreement between assessments were observed.

AB - BACKGROUND: An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization.OBJECTIVES: To develop an IGA scale, training module, and clinical certification examination for use in AD trials; establish content validity; and assess reliability.METHODS: Expert dermatologists participated in the development of the validated IGA for AD (vIGA-ADTM). Reliability (interrater and intrarater) was assessed by 2 web-based surveys. Clinical certification for investigators consisted of a training module and examination.RESULTS: Expert consensus was achieved around a 5-point IGA scale including morphologic descriptions, and content validity was established. Survey 1 showed strong interrater reliability (Kendall's coefficient of concordance W [Kendall's W], 0.809; intraclass correlation [ICC], 0.817) and excellent agreement (weighted kappa, 0.857). Survey 2, completed 5 months after training of dermatologists, showed improvements in scale reliability (Kendall's W, 0.819; ICC, 0.852; weighted kappa, 0.889). In this study, 627 investigators completed vIGA-AD training and certification.LIMITATIONS: Ratings were assessed on photographs.CONCLUSION: A validated IGA scale and training module were developed with the intent of harmonizing assessment of disease severity in AD trials. Strong reliability and excellent agreement between assessments were observed.

U2 - 10.1016/j.jaad.2020.04.104

DO - 10.1016/j.jaad.2020.04.104

M3 - SCORING: Journal article

C2 - 32344071

VL - 83

SP - 839

EP - 846

JO - J AM ACAD DERMATOL

JF - J AM ACAD DERMATOL

SN - 0190-9622

IS - 3

ER -